• Eight women with senile dementia and buccolinguofacial dyskinesias (BLFD) were given bromocriptine mesylate (from 2.5 to 20.0 mg daily). The frequency of their abnormal movements was quantitated by a method consisting of repeated counts (220 measurements per patient). In six patients, the mean frequency of BLFD was lower during bromocriptine mesylate therapy (even at daily doses of 10 mg or less) as compared with placebo; this result was statistically significant in four of the six. The second day after cessation of bromocriptine therapy, there seemed to be a rebound effect in six patients. These phenomena are discussed in light of the possible existence of presynaptic "autoreceptors" that would explain the paradoxical effects produced by a number of dopamine agonists.
Delwaide PJ, Hurlet A. Bromocriptine and Buccolinguofacial Dyskinesias in Patients With Senile Dementia: A Quantitative Study. Arch Neurol. 1980;37(7):441–443. doi:10.1001/archneur.1980.00500560071010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: